Rapha Capital Management specializes in identifying and investing in revolutionary ideas within medicine, healthcare, and technology sectors. The firm focuses on early-stage opportunities, particularly in Series A and Convertible Note rounds, with occasional participation in later stages such as Series C.

Notable portfolio companies include AsclepiX Therapeutics, which has raised $50 million for innovative ophthalmology treatments, and Poseida Therapeutics, with $142 million raised for cell and gene therapies. Rapha Capital Management's investment philosophy centers on recognizing transformative potential in healthcare and biotech innovations before they become widely apparent to other investors.